Absolute Quantification.
Seamless Proteomics.
NEW PUBLICATION
Read about the research behind our LiverEdge panel
Advancing Chronic Liver Disease Diagnoses: Targeted Proteomics for the Non-Invasive Detection of Fibrosis.
Villanueva Raisman, A., Kotol, D., Altay, O., Mardinoglu, A., Atak, D., Yurdaydin, C., … & Edfors, F. (2025). Livers, 5(1), 2.
Our Story
ProteomEdge™ is a company from Stockholm, Sweden, started by researchers at the Human Protein Atlas program (www.proteinatlas.org) and the national infrastructure Science for Life Laboratory (www.scilifelab.se).
The company is developing proprietary analysis platforms based on mass spectrometry to offer labeled protein standards for a wide range of protein targets of both clinical and research interest.
Our first product, ApoEdge™, was released November 1, 2023 and is a panel including all 18 different apolipoproteins for analyses of blood plasma. In April 2024 we released our DiscoveryEdge™175, a panel covering 176 interesting human protein targets, including complement factors, inflammatory markers, cancer markers and more. In June 2024, we introduced our ComplemEdge panel including 81 different proteins involved in the complement cascade and in August our LiverEdge panel with 39 liver disease related proteins was released.
One more targeted panel and a lager Discovery panel are in the pipeline, estimated to be released in 2025.
Vision
Bringing precision into absolute proteome quantification for next generation blood profiling.
Mission
Providing an analytical platform for state-of-the-art accuracy for absolute protein quantification using mass spectrometry.